Abstract
Incidence of neuroendocrine tumors (NETs) is increasing, including those of the gastroenteropancreatic tract. A proper understanding of the management of this disease has become necessary for the general surgeon. This article addresses current guidelines for diagnosis and localization of NETs, including somatostatin receptor PET. Updated treatment and outcomes of NETs by primary tumor site are discussed as well as those metastatic to the liver.
Keywords:
Appendix; Carcinoid; Liver metastases; Neuroendocrine; Pancreas; Small intestine.
Copyright © 2020 Elsevier Inc. All rights reserved.
MeSH terms
-
Biliary Tract Neoplasms / diagnosis
-
Biliary Tract Neoplasms / pathology
-
Biliary Tract Neoplasms / surgery*
-
Carcinoid Tumor / diagnosis
-
Carcinoid Tumor / pathology
-
Carcinoid Tumor / surgery
-
Cytoreduction Surgical Procedures
-
Gastrointestinal Neoplasms / diagnosis
-
Gastrointestinal Neoplasms / pathology
-
Gastrointestinal Neoplasms / surgery*
-
Humans
-
Intestine, Small / pathology
-
Intestine, Small / surgery
-
Liver Neoplasms / diagnosis
-
Liver Neoplasms / pathology
-
Liver Neoplasms / secondary
-
Liver Neoplasms / surgery
-
Lymphatic Metastasis / pathology
-
Neoplasm Staging
-
Neuroendocrine Tumors / diagnosis
-
Neuroendocrine Tumors / pathology
-
Neuroendocrine Tumors / surgery*
-
Pancreatic Neoplasms / diagnosis
-
Pancreatic Neoplasms / pathology
-
Pancreatic Neoplasms / surgery*
-
Positron-Emission Tomography
-
Prognosis
-
Receptors, Somatostatin / analysis